🇺🇸 FDA
Patent

US 11684612

Therapeutic uses of relacorilant, a heteroaryl-ketone fused azadecalin glucocorticoid receptor modulator

granted A61KA61K31/437A61K31/4745

Quick answer

US patent 11684612 (Therapeutic uses of relacorilant, a heteroaryl-ketone fused azadecalin glucocorticoid receptor modulator) held by Corcept Therapeutics Incorporated expires Mon Jun 22 2043 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Corcept Therapeutics Incorporated
Grant date
Tue Jun 27 2023 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Jun 22 2043 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
20
CPC classes
A61K, A61K31/437, A61K31/4745, A61P, A61P5/44